{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T20:01:28Z","timestamp":1791489688934,"version":"4.3.4"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2007,4,1]],"date-time":"2007-04-01T00:00:00Z","timestamp":1175385600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>We measured FGF23 concentrations in subjects with ADHR. FGF23 and serum phosphate correlated positively in controls and negatively in subjects with ADHR. Elevated FGF23 concentrations were associated with lower phosphate values. The variable phenotype in ADHR may be caused by fluctuations in FGF23.<\/jats:p>\n                  <jats:p>Introduction: Autosomal dominant hypophosphatemic rickets (ADHR) is a rare disorder of phosphaturia, hypophosphatemia, inappropriately low\/normal calcitriol, and rickets\/osteomalacia. ADHR is caused by mutations in a circulating peptide, fibroblast growth factor 23 (FGF23). We present the first report of FGF23 concentrations in subjects with ADHR. The aim was to test the hypotheses that subjects with ADHR have elevated FGF23 concentrations and that FGF23 concentrations are associated with disease severity.<\/jats:p>\n                  <jats:p>Materials and Methods: This was an observational study at a tertiary referral center. Subjects were from three kindreds with FGF23 mutations causing ADHR (n = 42). Controls were participants from these families without mutations (n = 55). Fasting blood and urine samples were obtained. Biochemistries were determined, and FGF23 concentrations were measured using two ELISAs.<\/jats:p>\n                  <jats:p>Results: Three cases are presented illustrating activity of disease and FGF23 concentrations. One case shows persistent hypophosphatemia and elevation of FGF23 concentrations, whereas another shows remission of hypophosphatemia corresponding to a decrease in previously elevated FGF23 concentrations. Overall cross-sectional group differences were nonsignificant for serum phosphate and FGF23 concentrations. C-terminal FGF23 concentration in controls was 61.0 \u00b1 28.6 (SD) RU\/ml (median, 52.5 RU\/ml), and in subjects with mutations was 148.8 \u00b1 374.5 RU\/ml (median, 63.1 RU\/ml). Mean intact FGF23 concentration in controls was 44.7 \u00b1 14.9 pg\/ml (median, 40.4 pg\/ml), and in subjects with mutations was 83.2 \u00b1 233.0 pg\/ml (median, 39.0 pg\/ml). C-terminal FGF23 concentrations were at least +2 SD in 10\/42(24%), and intact FGF23 concentrations were at least +2 SD in 3\/34(9%). Phosphate correlated positively with C-terminal and intact FGF23 in both controls and in subjects with mutations with phosphate &amp;gt;2.5 mg\/dl but correlated significantly negatively with C-terminal and intact FGF23 in ADHR subjects with phosphate \u22642.5 mg\/dl.<\/jats:p>\n                  <jats:p>Conclusions: Elevated FGF23 concentrations are associated with hypophosphatemia in ADHR, and remission of the phenotype is associated with lower FGF23 concentrations. FGF23 has an opposite relationship with phosphate in ADHR compared with controls. We conclude that ADHR symptoms and disease severity likely fluctuate with FGF23 concentrations.<\/jats:p>","DOI":"10.1359\/jbmr.070107","type":"journal-article","created":{"date-parts":[[2007,1,16]],"date-time":"2007-01-16T19:30:54Z","timestamp":1168975854000},"page":"520-526","source":"Crossref","is-referenced-by-count":158,"title":["FGF23 Concentrations Vary With Disease Status in Autosomal Dominant Hypophosphatemic Rickets"],"prefix":"10.1093","volume":"22","author":[{"given":"Erik A","family":"Imel","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Indiana University School of Medicine, Indianapolis, Indiana, USA"},{"name":"Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siu L","family":"Hui","sequence":"additional","affiliation":[{"name":"Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J","family":"Ecibs","sequence":"additional","affiliation":[{"name":"Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana, USA"},{"name":"Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2009,12,4]]},"reference":[{"key":"2024020319314391400_bib1","first-page":"287","article-title":"Familial hypophosphatemic rickets showing autosomal dominant inheritance","volume":"7","author":"Bianchine","year":"1971","journal-title":"Birth Defects Orig Artic Ser"},{"key":"2024020319314391400_bib2","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1681\/ASN.2005050573","article-title":"Fibroblast growth factor 23: Roles in health and disease","volume":"16","author":"Imel","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"2024020319314391400_bib3","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1210\/jcem.82.2.3765","article-title":"Autosomal dominant hypophosphatemic rickets\/osteomalacia: Clinical characterization of a novel renal phosphate wasting disorder","volume":"82","author":"Econs","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"2024020319314391400_bib4","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/81664","article-title":"Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23","volume":"26","author":"ADHR_Consortium","year":"2000","journal-title":"Nat Genet"},{"key":"2024020319314391400_bib5","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1046\/j.1523-1755.2001.00064.x","article-title":"Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23","volume":"60","author":"White","year":"2001","journal-title":"Kidney Int"},{"key":"2024020319314391400_bib6","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1210\/endo.143.8.8795","article-title":"Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo","volume":"143","author":"Shimada","year":"2002","journal-title":"Endocrinology"},{"key":"2024020319314391400_bib7","doi-asserted-by":"crossref","first-page":"9843","DOI":"10.1074\/jbc.M210490200","article-title":"The autosomal dominant hypophosphatemic rickets R176Q mutation in fibroblast growth factor 23 resists proteolytic cleavage and enhances in vivo biological potency","volume":"278","author":"Bai","year":"2003","journal-title":"J Biol Chem"},{"key":"2024020319314391400_bib8","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1210\/jc.2004-1039","article-title":"FGF-23 relationship to dietary phosphate and renal phosphate handling in healthy young men","volume":"90","author":"Ferrari","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"2024020319314391400_bib9","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1046\/j.1523-1755.2003.00328.x","article-title":"Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers","volume":"64","author":"Larsson","year":"2003","journal-title":"Kidney Int"},{"key":"2024020319314391400_bib10","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1359\/jbmr.060507","article-title":"Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women","volume":"21","author":"Burnett","year":"2006","journal-title":"J Bone Miner Res"},{"key":"2024020319314391400_bib11","doi-asserted-by":"crossref","first-page":"3144","DOI":"10.1210\/jc.2006-0021","article-title":"Dietary phosphorus regulates serum FGF-23 concentrations in healthy men","volume":"91","author":"Antoniucci","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"2024020319314391400_bib12","doi-asserted-by":"crossref","first-page":"5269","DOI":"10.1210\/en.2004-0233","article-title":"Transgenic mice overexpressing human fibroblast growth factor 23(R176Q) delineate a putative role for parathyroid hormone in renal phosphate wasting disorders","volume":"145","author":"Bai","year":"2004","journal-title":"Endocrinology"},{"key":"2024020319314391400_bib13","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1210\/en.2003-1768","article-title":"Transgenic mice expressing fibroblast growth factor 23 under the control of the [alpha]1(I) collagen promoter exhibit growth retardation, osteomalacia and disturbed phosphate homeostasis","volume":"145","author":"Larsson","year":"2004","journal-title":"Endocrinology"},{"key":"2024020319314391400_bib14","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1210\/jc.2005-2105","article-title":"Sensitivity of fibroblast growth factor 23 measurements in tumor induced osteomalacia","volume":"91","author":"Imel","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"2024020319314391400_bib15","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1056\/NEJMoa020881","article-title":"Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia","volume":"348","author":"Jonsson","year":"2003","journal-title":"N Engl J Med"},{"key":"2024020319314391400_bib16","doi-asserted-by":"crossref","first-page":"4957","DOI":"10.1210\/jc.2002-021105","article-title":"Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets\/osteomalacia","volume":"87","author":"Yamazaki","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"2024020319314391400_bib17","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(75)92736-1","article-title":"Nomogram for derivation of renal threshold phosphate concentration","volume":"306","author":"Walton","year":"1975","journal-title":"Lancet"},{"key":"2024020319314391400_bib18","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1359\/jbmr.2003.18.7.1227","article-title":"Serum FGF23 levels in normal and disordered phosphorus homeostasis","volume":"18","author":"Weber","year":"2003","journal-title":"J Bone Miner Res"},{"key":"2024020319314391400_bib19","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1210\/jcem-52-3-463","article-title":"X-linked hypophosphatemia: Effect of calcitriol on renal handling of phosphate, serum phosphate, and bone mineralization","volume":"52","author":"Costa","year":"1981","journal-title":"J Clin Endocrinol Metab"},{"key":"2024020319314391400_bib20","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1172\/JCI111900","article-title":"Healing of bone disease in X-linked hypophosphatemic rickets\/osteomalacia. Induction and maintenance with phosphorus and calcitriol","volume":"75","author":"Harrell","year":"1985","journal-title":"J Clin Invest"},{"key":"2024020319314391400_bib21","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1074\/jbc.M408903200","article-title":"Circulating FGF-23 is regulated by 1alpha,25-dihydroxyvitamin D3 and phosphorus in vivo","volume":"280","author":"Saito","year":"2005","journal-title":"J Biol Chem"},{"key":"2024020319314391400_bib22","doi-asserted-by":"crossref","first-page":"E1101","DOI":"10.1152\/ajpendo.00502.2004","article-title":"Vitamin D and phosphate regulate fibroblast growth factor-23 in K-562 cells","volume":"288","author":"Ito","year":"2005","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2024020319314391400_bib23","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1681\/ASN.2005111185","article-title":"Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D","volume":"17","author":"Liu","year":"2006","journal-title":"J Am Soc Nephrol"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1359%2Fjbmr.070107","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/22\/4\/520\/56552582\/5650220405.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/22\/4\/520\/56552582\/5650220405.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T10:48:23Z","timestamp":1710326903000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/22\/4\/520-526\/7597354"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,4,1]]},"references-count":23,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2009,12,4]]},"published-print":{"date-parts":[[2007,4,1]]}},"URL":"https:\/\/doi.org\/10.1359\/jbmr.070107","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2007,4,1]]},"published":{"date-parts":[[2007,4,1]]}}}